Treatment Strategies - Novel New Therapeutic Classes for Atherosclerotic Cardiovascular Disease


  • What have recent studies shown regarding residual CV risk in patients on statins?
  • What new agents are available to address residual risk?
  • What are the mechanisms of action of these therapeutics, and what patient populations do they benefit?
  • What are current AACE recommendations for the use of novel new therapeutic agents for ASCVD?
Download Slides (PDF)